We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




CerTest Biotec Opens New Facility for Diagnostic Products

By LabMedica International staff writers
Posted on 31 May 2018
CerTest Biotec (Zaragoza, Spain), a biotechnology company focused on the development and manufacturing of IVD diagnostic products, has opened a new facility in Spain for the research, development and manufacture of molecular diagnostics products.

CerTest develops, manufactures and sells a wide range of products for the identification of the agents causing infectious diseases in health facilities, laboratories and hospitals. More...
The company develops and provides clinical diagnostics products with high standards of quality, sensitivity, specificity and reproducibility, allowing the identification of pathogens at early stages of infection. It also collaborates with a large number of hospitals and research institutes in Spain and abroad.

The new facility, with a surface area of 4,500 square meters, comprises state-of-the-art laboratories, offices, warehouse and production and quality control areas, among others and has been set up at an investment of 5 million Euros. With this facility, CerTest Biotec will now have a total floor space of 7,000 square meters and will continue to expand in the field of molecular biology, which is one of the company’s specialties.

Related Links:
CerTest Biotec


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
All-in-One Molecular System
AIO M160
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.